Zolpidem sublingual - Paratek Pharmaceuticals

Drug Profile

Zolpidem sublingual - Paratek Pharmaceuticals

Alternative Names: Intermezzo; Zolpidem hemitartrate; Zolpidem lozenge; Zolpidem tartrate; Zolpidem tartrate lozenge; Zolpidem tartrate sublingual; Zolpidem tartrate sublingual tablet; Zolpidem tartrate sublingual tablet C-IV

Latest Information Update: 01 Nov 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TransOral Pharmaceuticals
  • Developer Paratek Pharmaceuticals
  • Class Acetamides; Hypnosedatives; Pyridines; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Insomnia

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 30 Oct 2014 Transcept Pharmaceuticals Inc merged into Paratek Pharmaceuticals and is now called Paratek Pharmaceuticals
  • 10 May 2012 Pharmacokinetics data from a clinical trial in healthy volunteers presented at the annual meeting of the American Psychiatric Association (APA-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top